Cinnarizine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Labyrinthine disorder
Adult: For symptoms of labyrinthine disorders, including dizziness, vertigo, tinnitus, nystagmus, nausea and vomiting: As tab: 25 mg or 30 mg tid. As cap: 75 mg once daily. Dosage recommendations may vary among individual products or between countries (refer to detailed product guidelines).
Child: As 15 mg tab: 5-12 years 15 mg tid; >12 years Same as adult dose.

Oral
Cerebrovascular disorders
Adult: As cap: 75 mg once daily.

Oral
Prophylaxis of motion sickness
Adult: As 15 mg tab: Initially, 30 mg to be taken 2 hours before travel, then 15 mg 8 hourly during the journey if necessary. As 25 mg tab: 25 mg to be taken at least 30 minutes before travel, may be repeated 6 hourly if necessary. Dosage recommendations may vary among individual products or between countries (refer to detailed product guidelines).
Child: As 15 mg tab: 5-12 years Initially, 15 mg to be taken 2 hours before travel, then 7.5 mg 8 hourly during the journey if necessary; >12 years Same as adult dose. As 25 mg tab: 6-12 years 12.5 mg to be taken at least 30 minutes before travel, may be repeated 6 hourly if necessary; ≥13 years Same as adult dose. Dosage recommendations may vary among individual products or between countries (refer to detailed product guidelines).

Oral
Peripheral circulatory disorders
Adult: As 25 mg tab: 50-75 mg 2-3 times daily. Max: 225 mg daily.
Cách dùng
Should be taken with food.
Thận trọng
Patient with Parkinson's disease. Avoid use in a patient with porphyria. Renal and hepatic impairment. Children. Pregnancy. Not recommended for use during breastfeeding.
Tác dụng không mong muốn
Significant: Epigastric discomfort, drowsiness; new-onset or aggravation of parkinsonian symptoms.
Gastrointestinal disorders: Nausea, vomiting, dry mouth.
General disorders and administration site conditions: Fatigue.
Immune system disorders: Hypersensitivity reaction.
Investigations: Increased weight.
Nervous system disorders: Headache.
Psychiatric disorders: Hypersomnia.
Skin and subcutaneous tissue disorders: Hyperhidrosis, lichenoid keratosis (including lichen planus).
Thông tin tư vấn bệnh nhân
This drug may cause drowsiness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor for new-onset or aggravation of parkinsonian symptoms.
Quá liều
Symptoms: Vomiting, extrapyramidal symptoms, hypotonia, seizures, and altered consciousness (ranging from somnolence to stupor and coma). Management: Supportive and symptomatic treatment.
Tương tác
May potentiate sedative effects with CNS depressants (e.g. barbiturates, hypnotics, opioid analgesics, antipsychotic agents, anxiolytics) or TCAs.
Tương tác với thức ăn
Alcohol may potentiate the sedative effects of cinnarizine.
Ảnh hưởng đến kết quả xét nghiệm
May cause a false-negative result to dermal reactivity indicators when used within 4 days before skin testing.
Tác dụng
Description:
Mechanism of Action: Cinnarizine, a piperazine derivative, has antihistamine, sedative, and Ca channel blocking activity. It selectively inhibits the Ca influx into the depolarised cells in the vascular smooth muscle, thus decreasing the availability of free Ca ions for induction and maintenance of contraction. It has also been shown to be a non-competitive antagonist of smooth muscle contractions caused by various vasoactive agents (including histamine). Additionally, it suppresses nystagmus and other autonomic disturbances by preventing the stimulation of the vestibular system.
Pharmacokinetics:
Absorption: Absorbed from the gastrointestinal tract (relatively slow). Time to peak plasma concentration: 1-4 hours.
Distribution: Plasma protein binding: 91%.
Metabolism: Extensively metabolised primarily by CYP2D6 isoenzyme.
Excretion: Via faeces (approx 67%) and urine (approx 33%) as metabolites. Elimination half-life: 4-24 hours.
Đặc tính

Chemical Structure Image
Cinnarizine

Source: National Center for Biotechnology Information. PubChem Database. Cinnarizine, CID=1547484, https://pubchem.ncbi.nlm.nih.gov/compound/Cinnarizine (accessed on Jan. 21, 2020)

Bảo quản
Store between 15-30°C. Protect from light.
Phân loại MIMS
Thuốc trị chóng mặt / Thuốc giãn mạch ngoại biên & thuốc hoạt hóa não
Phân loại ATC
N07CA02 - cinnarizine ; Belongs to the class of antivertigo preparations.
Tài liệu tham khảo
Anon. Cinnarizine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/02/2022.

Buckingham R (ed). Cinnarizine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/02/2022.

Dizzinon Forte 75 mg Capsule (Lloyd Laboratories, Inc.). MIMS Philippines. http://www.mims.com/philippines. Accessed 03/02/2022.

Joint Formulary Committee. Cinnarizine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/02/2022.

Stugeron (Johnson & Johnson Pte Ltd.). MIMS Singapore. http://www.mims.com/singapore. Accessed 14/03/2022.

Stugeron 15 mg Tablets (Janssen-Cilag Limited). MHRA. https://products.mhra.gov.uk. Accessed 03/02/2022.

Stugeron 25 mg Tablets (Johnson & Johnson Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 03/02/2022.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Cinnarizine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Becostugon
  • Brawmicin
  • Cinarex 25
  • Cinarizin Nam Hà
  • Cinnarex
  • Cinnarizin Actavis
  • Cinnarizin Balkanpharma
  • Cinnarizin DOMESCO
  • Cinnarizin Quapharco
  • Cinnarizin Traphaco
  • Devomir
  • Diziron
  • Dovomir
  • Goodrizin
  • Medozin
  • Pyme Cinazin
  • Stagerin
  • Stugeron
  • Stugeron-Richter
  • Stugon-Pharimex
  • Vertizon
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in